These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15167162)

  • 1. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
    Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
    Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
    Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
    Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
    Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
    AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.
    Günel N; Coşkun U; Toruner FB; Sancak B; Yilmaz E; Cengiz O; Elbeg S; Uner A; Ozkan S
    Curr Med Res Opin; 2003; 19(1):47-50. PubMed ID: 12661780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
    Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
    Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
    Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
    Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen therapy and hepatic steatosis.
    Coskun U; Törüner FB; Günel N
    Neoplasma; 2002; 49(1):61-4. PubMed ID: 12044063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
    Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
    Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients.
    Chang HT; Pan HJ; Lee CH
    Clin Breast Cancer; 2018 Aug; 18(4):e677-e685. PubMed ID: 29287963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
    Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
    Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size and oxidative susceptibility of low-density lipoprotein particles in breast cancer patients with tamoxifen-induced fatty liver.
    Wakatsuki A; Ogawa Y; Saibara T; Okatani Y; Fukaya T
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3676-81. PubMed ID: 12161495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cirrhosis with steatohepatitis after adjuvant tamoxifen.
    Oien KA; Moffat D; Curry GW; Dickson J; Habeshaw T; Mills PR; MacSween RN
    Lancet; 1999 Jan; 353(9146):36-7. PubMed ID: 10023952
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.
    Yoo JJ; Lim YS; Kim MS; Lee B; Kim BY; Kim Z; Lee JE; Lee MH; Kim SG; Kim YS
    PLoS One; 2020; 15(7):e0236506. PubMed ID: 32730287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S
    Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients.
    Yang YJ; Kim KM; An JH; Lee DB; Shim JH; Lim YS; Lee HC; Lee YS; Ahn JH; Jung KH; Kim SB
    Breast; 2016 Aug; 28():67-72. PubMed ID: 27240168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.